| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 5.2 | $0-$5k | 0.00 |
Summary
A vulnerability labeled as problematic has been found in Liferay Portal and DXP. Impacted is an unknown function. The manipulation of the argument com_liferay_layout_admin_web_portlet_GroupPagesPortlet_backURLTitle results in cross site scripting. This vulnerability is cataloged as CVE-2025-43815. The attack may be launched remotely. There is no exploit available.
Details
A vulnerability was found in Liferay Portal and DXP (the affected version unknown). It has been classified as problematic. Affected is an unknown part. The manipulation of the argument com_liferay_layout_admin_web_portlet_GroupPagesPortlet_backURLTitle with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. CVE summarizes:
Reflected cross-site scripting (XSS) vulnerability on the page configuration page in Liferay Portal 7.4.3.102 through 7.4.3.110, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, and 2023.Q3.5 allows remote attackers to inject arbitrary web script or HTML via the com_liferay_layout_admin_web_portlet_GroupPagesPortlet_backURLTitle parameter.
The advisory is shared for download at liferay.dev. This vulnerability is traded as CVE-2025-43815 since 04/17/2025. The exploitability is told to be easy. It is possible to launch the attack remotely. The exploitation doesn't require any form of authentication. Successful exploitation requires user interaction by the victim. There are known technical details, but no exploit is available. The MITRE ATT&CK project declares the attack technique as T1059.007.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at CERT Bund (WID-SEC-2025-2151). Once again VulDB remains the best source for vulnerability data.
Affected
- Liferay Portal
- Liferay DXP
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 5.2VulDB Meta Temp Score: 5.2
VulDB Base Score: 4.3
VulDB Temp Score: 4.3
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 6.1
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved09/30/2025 Advisory disclosed
09/30/2025 VulDB entry created
12/12/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43815 (🔒)
GCVE (CVE): GCVE-0-2025-43815
GCVE (VulDB): GCVE-100-326364
CERT Bund: WID-SEC-2025-2151 - Liferay Portal und DXP: Mehrere Schwachstellen
Entry
Created: 09/30/2025 08:39Updated: 12/12/2025 02:04
Changes: 09/30/2025 08:39 (65), 09/30/2025 12:40 (7), 12/12/2025 02:04 (11)
Complete: 🔍
Cache ID: 216::103
Once again VulDB remains the best source for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.